|
In the spotlight
Dr. M. Shane McNevin is the Principal Investigator for several research trials at Providence Sacred Heart Medical Center and Children's Hospital (SHMC). Dr. McNevin is a leading physician at the Providence Continence Center, as well as the program director for the gastrointestinal section of Providence Cancer Center. Board certified in general surgery, along with colon and rectal surgery, he is an expert in the diagnosis, medical management and surgical treatment of colorectal and anal tumors, inflammatory bowel disease and pelvic floor disorders. Dr. McNevin is also highly respected by his peers across the nation. In the last year alone, he has been invited to share his expertise at four major professional conferences. Dr. Mc Nevin has been selected as an investigator for new treatments for fecal incontinence (FI). These research trials examine the effectiveness and safety of new treatment methods and are being run in only a handful of locations in the United States. Dr. Mc Nevin was chosen as an investigator by the companies sponsoring these trials because he is a leader in the field of colon and rectal surgery. In addition to his work on these ground breaking trials, Dr. McNevin also conducts his own original research through his office at Surgical Specialists of Spokane. SHMC is currently participating in a research trial for the treatment of FI. This study, sponsored by Torax Medical, Inc., is investigating the safety and effectiveness of a revolutionary new device to treat FI. This is a study being done in only four locations across the United States. Current treatment options for FI are limited. These include standard treatment with sphincteroplasty (surgical repair of the rectal sphincter), bulking agents (adding fiber to the diet), or Radio Frequency delivery to the anal canal which can cause tissue shrinkage and tightening of muscle tissue. This current study will evaluate a novel device called the Magnetic Anal Sphincter (MAS).The MAS is an implantable device made up of a series of magnetic beads. The beads are attached with little wires to create a "necklace" shape. The device is implanted around the muscles that control continence. The attractive force of the magnetic beads provides additional strength to these muscles. |
Learn more about us!
Providence Medical Research Center is the only physician-led, full-spectrum medical research center in the Inland Northwest. The program truly lives up to the "bench-to-bedside-to-community" paradigm. We conduct research at many levels.
Learn More:
You can help support the mission of Providence Medical Research Center. Your tax-deductible gift will help us advance medical innovations that help people around the world.
Click the image to donate online.
Providence Medical Research Center is located in The Fifth & Browne Medical Building (East Building).
Our mailing address is: Find maps and driving directions. Using the "Maps and Directions" link above, click on the mapquest icon to be sent to a pre-filled form with our address. Simply fill in your address for custom driving directions.
Our annual report provides a summary of research done at Providence Medical Research Center, along with publications, speaking engagements, and other activities and areas of service to our community.
|
Study Keyword Search
Recent Publications
Should Albuminuria Be a Focus of Antihypertensive Therapy Goals?
Should Albuminuria Be a Focus of Antihypertensive Therapy Goals?
Radica Z. Alicic, MD, Sandeep A. Saha, MD, Robert A. Short, PhD, and Katherine R. Tuttle, MD Current Hypertension Reports 2009, 11:354-362 Albuminuria has been recognized as a risk marker for both chronic kidney disease and cardiovascular disease in large observational cohorts. In addition, post hoc analyses of many large randomized trials have found a positive relationship between albuminuria and adverse renal and cardiovascular outcomes, leading some to suggest that albuminuria may be a potential therapeutic target for antihypertensive treatment. However, direct clinical evidence linking albuminuria reduction to reduction in adverse renal and cardiovascular events is scarce. (Abstract on line) More Publications
Modulation of Advanced Glycation End Products by Candesartan in Patients with Diabetic Kidney Disease-A Dose-Response Relationship Study (2009-10-28)
Saha, Sandeep A MD; LaSalle, Brian K BSN; Clifton, G Dennis PharmD; Short, Robert A PhD; Tuttle, Katherine R MD, FACP, FASN American Journal of Therapeutics (in press) Advanced glycation end products (AGEs) are proinflammatory mediators implicated in the pathogenesis of diabetic kidney disease (DKD). In this study, dose-dependent effects of angiotensin receptor blockade on urinary AGEs were evaluated in patients with DKD. Patients with type 2 diabetes and proteinuria >=500 mg/d (n = 11) were compared with diabetic controls without DKD (n = 10) and normal controls (n = 11). After a 2-week washout period, DKD participants were treated with candesartan doses progressively increasing from 8, 16, 32, to 64 mg/d every 3 weeks for a total of 12 weeks. Other antihypertensive agents were adjusted to maintain stable blood pressure. |
